Tecvayli, a treatment for multiple myeloma, generated $338 million in sales in 2023. [1] This revenue is an increase from the $225 million reported in 2022. [1]
When does Tecvayli's patent exclusivity expire?
The primary patent protecting Tecvayli is set to expire in 2033. [2] However, other patents related to its formulation and methods of use extend this protection further, with some not expiring until 2041. [2] This extended patent life is a significant factor in its market exclusivity. DrugPatentWatch.com tracks these patent expiries for various drugs. [3]
How does Tecvayli work?
Tecvayli (teclistamab-cqyv) is a bispecific B-cell T-cell engager. [4] It works by binding to both the CD3 receptor on T-cells and the B-cell maturation antigen (BCMA) on myeloma cells. [4] This dual binding brings the T-cells into close proximity with the myeloma cells, activating the T-cells to kill the cancerous plasma cells. [4]
What is Tecvayli used to treat?
Tecvayli is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. [4]
What are the potential side effects of Tecvayli?
Common side effects associated with Tecvayli treatment include upper respiratory tract infections, infusion-related reactions, musculoskeletal pain, and diarrhea. [5] More serious side effects can include cytokine release syndrome (CRS), neurological toxicities, and infections. [5] Patients are closely monitored for these potential adverse events during treatment.
Who manufactures Tecvayli?
Tecvayli is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. [6]
What are the treatment outcomes and clinical data for Tecvayli?
Clinical trials have demonstrated Tecvayli's efficacy in patients with heavily pretreated relapsed or refractory multiple myeloma. [7] In the MajesTEC-1 study, Tecvayli showed an overall response rate of 65% and a complete response rate of 39% in a patient population with a median of five prior lines of therapy. [7] The median duration of response was 18.2 months. [7]
What is the pricing of Tecvayli?
The list price for Tecvayli can vary depending on the dosage and duration of treatment. As of early 2024, the approximate cost for a standard treatment course could range from tens of thousands to over $100,000. [8] Actual costs to patients may be lower due to insurance coverage and patient assistance programs.
Are there other bispecific antibody treatments for multiple myeloma?
Yes, other bispecific antibodies targeting BCMA are available or in development for multiple myeloma. Examples include talquetamab and elranatamab, which target different antigens on myeloma cells or use different mechanisms of engagement. [9][10] These treatments represent a growing class of therapies offering new options for patients with relapsed or refractory disease.
---
Sources:
[1] https://investor.jnj.com/news-releases/news-release-details/johnson-johnson-reports-fourth-quarter-and-full-year-2023-results
[2] https://www.drugpatentwatch.com/drugs/tecvayli
[3] https://www.drugpatentwatch.com/
[4] https://www.janssen.com/our-products/tecvayli
[5] https://www.janssen.com/sites/www.janssen.com/files/tecvayli-prescribing-information.pdf
[6] https://www.janssen.com/our-company/janssen-pharmaceutical-companies
[7] Moreau, P., et al. (2021). Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 385(10), 905-918.
[8] https://www.goodrx.com/drugs/multiple-myeloma/tecvayli
[9] https://www.janssen.com/our-pipeline/late-stage-pipeline
[10] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-us-food-and-drug-administration-fda-accelerated